What's happening
Writing a plain-English summary… Track this bill to get it by email.
Why it matters
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Sponsors
1 Co-sponsor
History
- Referred to higher education
- Returned to assembly
- Repassed senate
- Amended on third reading (t) 7125a
- Vote reconsidered - restored to third reading
- Returned to senate
- Recalled from assembly
- Referred to higher education
- Delivered to assembly
- Passed senateVote 59–0
- Ordered to third reading cal.1126
- Committee discharged and committed to rules
Show 1 earlier action
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Provides for the substitution of opioid analgesic drugs incorporating abuse-deterrent technology for opioid analgesic drugs under certain circumstances
In Assembly Committee · Higher Education · Sponsor Michael Cusick
Full text
The text isn't available here yet. Check nysenate.gov.
Sponsor's memo
BILL NUMBER:S7125A
Title of bill
An act to amend the public health law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs
Purpose or general idea of bill
To help prevent the abuse and diversion of opioid drugs by ensuring that opioid drugs which incorporate abuse-deterrent technologies are dispensed whenever possible.
Summary of specific provisions
Section 1 adds a new section 3340 to the Public health law to prohibit the substitution of opioids which have abuse-deterrent technologies with those which do not have such abuse-deterrent technologies without the consent of the prescribing physician.
Section 2 is the effective date of the bill.
Justification
While pain management is an important and integral part of the health care system, abuse and diversion of opioids has necessitated the implementation of anti-abuse policies. These policies need to be approached comprehensively by government, law enforcement, health care providers and manufacturers and an important component is to ensure that opioids incorporating abuse-deterrent technologies are dispensed whenever possible.
The U.S. Food and Drug Administration (FDA) has recognized that the development and implementation of abuse-deterrent technologies is an important "step towards the goal of creating safer opioid(s)...." In recently published FDA guidance on abuse-deterrent technologies for opioids, the FDA provided that they "consider[s] the development of these products a high public health priority."
Under this proposal, when a physician prescribes an opioid drug that incorporates abuse-deterrent technologies, no substitution or interchange shall be permitted for that drug without the pharmacy, (1) verifying that the substitute provides substantially similar abuse-deterrent properties, or (2) obtaining the prior, written consent of the prescribing physician.
While New York State has been at the forefront of fighting prescription drug abuse, it is imperative that the State continue to strengthen its laws and protect against abuse while enhancing the integrity of its health care system. Enacting this proposal will be consistent with these goals and with the priorities set out by the FDA.
Prior legislative history
New Bill.
Fiscal implications
None
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.